CONCLUSIONS The effects of treatment with clomipramine and selective serotonin reuptake inhibitors ( SSRIs : fluvoxamine , sertraline , fluoxetine , citalopram , and escitalopram ) proved to be similar , except for the lower adherence rate in case of clomipramine because of its side effects .
PURPOSE This systematic review examines the efficacy of pharmacological therapy for obsessive-compulsive disorder ( OCD ) , addressing two major issues : which treatment is most effective in treating the patient 's symptoms and which is beneficial for maintaining remission .
Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series.
BACKGROUND AND METHODS The adverse effects and potential clinical value of risperidone as augmentation to selective serotonin reuptake inhibitor ( SSRI ) treatment in treatment resistant severe adolescent OCD patients were examined in 17 adolescents ( 15 - 19 years old , 8 males and 9 females ) in an open label trial of risperidone  1 - 2 mg daily . RESULTS After 12 weeks of augmenting treatment , statistically significant improvements were reflected in OCD symptom ratings ( mean total Y-BOCS/CY-BOCS scores after treatment with second SSRI 24.2 + /- 2.6 versus 19.9 + /- 2.9 , p < 0.001 ) and global assessment scores ( mean CGAS , 69.4 + /- 11.4 versus 74.7 + /- 9.6 , p < 0.001 ) . Four patients had moderate improvement of more than 25 % reduction in Y-BOCS scores in OCD symptoms . Further 10 patients had a reduction of 10 - 25 % in total score , indicating slight improvement . One patient ( 6 % ) dropped from clinical OCD to a sub clinical level of OCD ( Y-BOCS total score < 15 ) . No patient was found to have worsened during augmentation treatment . Eight cases had weight gain and sedation was reported in four cases . CONCLUSION These preliminary findings suggest that augmentation with risperidone in dosages up to 2 mg daily might be efficient in adolescents with treatment resistant OCD
CONCLUSIONS The effects of treatment with clomipramine and selective serotonin reuptake inhibitors ( SSRIs : fluvoxamine , sertraline , fluoxetine , citalopram , and escitalopram ) proved to be similar , except for the lower adherence rate in case of clomipramine because of its side effects .
PURPOSE This systematic review examines the efficacy of pharmacological therapy for obsessive-compulsive disorder ( OCD ) , addressing two major issues : which treatment is most effective in treating the patient 's symptoms and which is beneficial for maintaining remission .